{"id":"W4398255879","doi":"10.1017/cjn.2024.92","title":"D.1 Efficacy, safety, and tolerability of subcutaneous efgartigimod in chronic inflammatory demyelinating polyneuropathy: results from the ADHERE trial","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"Autoimmune Bullous Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Workers Compensation Board of Alberta","funders":"","keywords":"Medicine; Chronic inflammatory demyelinating polyneuropathy; Tolerability; Adverse effect; Placebo; Internal medicine; Randomized controlled trial; Multifocal motor neuropathy; Gastroenterology; Autoantibody; Antibody; Polyradiculoneuropathy; Clinical trial; Surgery; Immunology; Mismatch negativity; Pathology; Guillain-Barre syndrome","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001012145,0.00078291,0.001527844,0.0002122418,0.0002305861,0.000827521,0.0005313296,0.001119849,0.004990394],"category_scores_gemma":[0.00109824,0.0001920685,0.00137905,0.0002216891,0.0004446626,0.0004864754,0.0003382803,0.001594531,0.00059671],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003902437,"about_ca_system_score_gemma":0.0002830696,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006755724,"about_ca_topic_score_gemma":0.00195969,"domain_scores_codex":[0.9995419,0.0002167165,0.00003657732,0.00006679358,0.00006633045,0.00007168167],"domain_scores_gemma":[0.9995795,0.0001055819,0.0001457904,0.00003655805,0.00004436224,0.00008832098],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8956451,0.003863232,0.007657012,0.003382955,0.005401322,0.0001585717,0.00008821689,0.0008135603,0.006412538,0.000414761,0.005354093,0.07080853],"study_design_scores_gemma":[0.8310004,0.1106438,0.04585036,0.0005000284,0.004774375,0.0003257996,0.0000985747,0.00104236,0.001102244,0.0006040543,0.004002128,0.00005583713],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9728948,0.01565666,0.0002989539,0.0008299444,0.0002766723,0.0007298773,0.002655159,0.000097507,0.006560397],"genre_scores_gemma":[0.9871974,0.00390597,0.000577552,0.001837835,0.0004049763,0.0008666995,0.002184432,0.00001333597,0.003011883],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004990394,"threshold_uncertainty_score":0.01669455,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02501606332799626,"score_gpt":0.276966499597633,"score_spread":0.2519504362696367,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}